Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.

NCT07269041 is registered in ClinicalTrials.gov with University of California, Los Angeles as lead sponsor.

NCT NCT07269041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07269041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Feasibility Study of HSPC Infusion Following Total Lymphoid Irradiation and Anti-thymocyte Globulin in Patients With a Pre-existing, Well-functioning HLA-matched Living-donor Liver Transplant to Induce Immune Tolerance.
Lead sponsor
University of California, Los Angeles
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 20, 2026
Completion date
January 31, 2033
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chimerism, end stage liver disease, graft survival, hematopoietic stem cell, immune tolerance, immune tolerance/drug effects, immunosuppression after liver transplantation, immunosuppression disorders, liver transplantation